Kulaylat Audrey S, Hollenbeak Christopher S, Stewart David B
1 Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, Pennsylvania State University, Hershey, Pennsylvania 2 Department of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, Pennsylvania.
Dis Colon Rectum. 2017 Sep;60(9):922-927. doi: 10.1097/DCR.0000000000000881.
Squamous cell cancers of the anus are rare GI malignancies for which neoadjuvant chemoradiation is the first-line treatment for nonmetastatic disease. Squamous cancers of the rectum are far less common, and it is unclear to what degree chemoradiotherapy improves their outcomes.
The purpose of this study was to compare stage-specific survival for anal and rectal squamous cancers stratified by treatment approach.
This was a retrospective cohort study.
The study was conducted at Commission on Cancer designated hospitals.
Patients (2006-2012) identified in the National Cancer Database with pretreatment clinical stage I to III cancers who underwent chemoradiotherapy, with and without subsequent salvage surgical resection (low anterior resection or abdominoperineal resection), ≥12 weeks after chemoradiotherapy were included in the study.
Overall survival and the need for salvage surgery were measured.
Anal cancers (n = 11,224) typically presented with stage II (45.7%) or III (36.3%) disease, whereas rectal cancer stages (n = 1049) were more evenly distributed (p < 0.001). More patients with rectal cancer underwent low anterior or abdominoperineal resections 12 weeks or later after chemoradiotherapy versus those undergoing abdominoperineal resection for anal cancer (3.8% versus 1.2%; p < 0.001). Stage I and II rectal cancer was associated with poorer survival compared with anal cancer (stage I, p = 0.017; stage II, p < 0.001); survival was similar for stage III disease. Salvage surgery for anal cancer was associated with worse survival for stage I to III cancers; salvage surgery did not significantly affect survival for rectal cancer.
This was a retrospective study without cancer-specific survival measures.
Squamous rectal cancers are associated with significantly worse survival than squamous cancers of the anus for clinical stage I and II disease. Despite both cancers exhibiting squamous histology, rectal cancers may be less radiosensitive than anal cancers, as suggested by the greater incidence of salvage surgery that does not appear to significantly improve overall survival. See Video Abstract at http://links.lww.com/DCR/A422.
肛门鳞状细胞癌是罕见的胃肠道恶性肿瘤,对于非转移性疾病,新辅助放化疗是一线治疗方法。直肠鳞状细胞癌则更为少见,目前尚不清楚放化疗能在多大程度上改善其治疗效果。
本研究旨在比较根据治疗方法分层的肛门和直肠鳞状细胞癌的特定分期生存率。
这是一项回顾性队列研究。
该研究在癌症委员会指定的医院进行。
纳入2006年至2012年期间在国家癌症数据库中识别出的临床分期为I至III期、接受放化疗(无论是否随后进行挽救性手术切除,即低位前切除术或腹会阴联合切除术)且放化疗后≥12周的患者。
测量总生存率和挽救性手术的必要性。
肛门癌(n = 11,224)通常表现为II期(45.7%)或III期(36.3%)疾病,而直肠癌分期(n = 1049)分布更为均匀(p < 0.001)。与接受腹会阴联合切除术的肛门癌患者相比,更多直肠癌患者在放化疗12周或更晚后接受低位前切除术或腹会阴联合切除术(3.8%对1.2%;p < 0.001)。与肛门癌相比,I期和II期直肠癌患者的生存率较差(I期,p = 0.017;II期,p < 0.001);III期疾病的生存率相似。肛门癌的挽救性手术与I至III期癌症患者较差的生存率相关;挽救性手术对直肠癌患者的生存率没有显著影响。
这是一项回顾性研究,没有癌症特异性生存指标。
对于临床I期和II期疾病,直肠鳞状细胞癌的生存率明显低于肛门鳞状细胞癌。尽管两种癌症均表现为鳞状组织学,但直肠癌的放射敏感性可能低于肛门癌,这表现为挽救性手术发生率更高,而挽救性手术似乎并未显著提高总生存率。见视频摘要:http://links.lww.com/DCR/A422 。